The EU’s drug regulator has approved the use of two monoclonal antibody treatments for Covid-19, clearing the way for the use of the Regeneron-Roche and Celltrion therapies amid a rise in cases on the continent.
The European Medicines Agency (EMA), in a Thursday statement, recommended that Regeneron Roche be approved for adult and juvenile patients over 12 years old. However, it suggested that Celltrion should only ever be administered to adults.
Regeneron-Roche’s Ronapreve and Celltrion’s Regkirona are the first monoclonal antibody treatments for Covid to be recommended for market authorization by the EMA’s human medicines committee (CHMP).
The treatments work by attaching themselves to a specific target – in this case, the spike protein in the coronavirus – helping to alleviate symptoms and reduce the risk of hospitalization and death.
As the EU grapples with growing Covid cases across its member countries, and as the winter months approach, a lot of healthcare services worry that they may not be equipped to handle the combined coronavirus-seasonal flu infection.
You think your friends might be interested in this story? Tell your friends!